Morgan Stanley Adjusts Price Target on Editas Medicine to $10 From $15, Maintains Underweight Rating - Marketscreener.com

2 years ago 51

Homepage Equities United States Nasdaq Editas Medicine, Inc. News Summary     EDIT   US28106W1036 (EDIT) Add to my list   Report Real-time Estimate Cboe BZX  -  11:36 2022-11-08 americium EST 11.59 USD   +4.94% 11:26a Morgan Stanley Adjusts Price Target connected Editas Medicine to $10 From $15, Maintains Underweight Rating MT 11/03 Baird Adjusts Editas Medicine's Price Target to $25 From $30, Keeps Outperform Rating MT 11/03 Chardan Trims Price Target for Editas Medicine to $43 From $60, Maintains Buy Rating MT Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds   Summary Most relevant All News Analyst Reco. Other languages Press Releases Official Publications Sector news 11/08/2022 | 11:26am EST MT Newswires 2022 All quality about EDITAS MEDICINE, INC. 11:26a Morgan Stanley Adjusts Price Target connected Editas Medicine to $10 From $15, Maintains Under.. MT 11/03 Baird Adjusts Editas Medicine's Price Target to $25 From $30, Keeps Outperform Rating MT 11/03 Chardan Trims Price Target for Editas Medicine to $43 From $60, Maintains Buy Rating MT 11/03 RBC Cuts Price Target connected Editas Medicine to $32 From $40, Maintains Sector Perform Rati.. MT 11/02 EDITAS MEDICINE, INC. Management's Discussion and Analysis of Financial Condition and .. AQ 11/02 Transcript : Editas Medicine, Inc., Q3 2022 Earnings Call, Nov 02, 2022 CI 11/02 Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months En.. CI 11/02 Editas : Q3 Earnings Snapshot AQ 11/02 Editas Medicine Announces Third Quarter 2022 Results and Business Updates GL 11/02 Editas Medicine Announces Third Quarter 2022 Results and Business Updates AQ Analyst Recommendations on EDITAS MEDICINE, INC. 11:26a Morgan Stanley Adjusts Price Target connected Editas Medicine to $10 From $15, Maintains Under.. MT 11/03 Baird Adjusts Editas Medicine's Price Target to $25 From $30, Keeps Outperform Rating MT 11/03 Chardan Trims Price Target for Editas Medicine to $43 From $60, Maintains Buy Rating MT Financials (USD) Sales 2022 17,1 M - - Net income 2022 -222 M - - Net currency 2022 360 M - - P/E ratio 2022 -3,43x Yield 2022 - Capitalization 743 M 743 M - EV / Sales 2022 22,4x EV / Sales 2023 24,0x Nbr of Employees 264 Free-Float 99,5% Chart EDITAS MEDICINE, INC. Duration : Period : Technical investigation trends EDITAS MEDICINE, INC. Short Term Mid-Term Long Term Trends Bearish Neutral Neutral Income Statement Evolution Consensus Sell Buy Mean consensus OUTPERFORM Number of Analysts 18 Last Close Price 11,04 $ Average people price 26,20 $ Spread / Average Target 137% EPS Revisions Managers and Directors Gilmore ONeill President, Chief Executive Officer & Director Michelle Robertson Chief Financial Officer & Treasurer James C. Mullen Executive Chairman Mark S. Shearman Chief Scientific Officer & Executive VP Mei Baisong Chief Medical Officer & Senior Vice President Sector and Competitors 1st jan. Capi. (M$) EDITAS MEDICINE, INC. -58.42% 743 MODERNA, INC. -35.41% 63 021 IQVIA HOLDINGS INC. -26.28% 38 632 LONZA GROUP AG -36.50% 36 235 ALNYLAM PHARMACEUTICALS, INC. 20.85% 25 212 SEAGEN INC. -16.05% 24 097

1. Homepage
2. Health
3. Morgan Stanley Adjusts Price Target on Editas Medicine to $10 From $15, Maintains Underweight Rating - Marketscreener.com